Difference between revisions of "Epidermal growth factor receptor inhibitors"

From Libre Pathology
Jump to navigation Jump to search
m (w)
(+TKI)
Line 2: Line 2:


==Drugs==
==Drugs==
*Gefitinib (Iressa).<ref name=pmid20855837/>  
*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>  
*Erlotinib (Tarceva)).<ref name=pmid20855837>{{cite journal |author=Sun Y, Ren Y, Fang Z, ''et al.'' |title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases |journal=J. Clin. Oncol. |volume=28 |issue=30 |pages=4616–20 |year=2010 |month=October |pmid=20855837 |doi=10.1200/JCO.2010.29.6038 |url=}}</ref>
*[[Erlotinib]] (Tarceva)).<ref name=pmid20855837>{{cite journal |author=Sun Y, Ren Y, Fang Z, ''et al.'' |title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases |journal=J. Clin. Oncol. |volume=28 |issue=30 |pages=4616–20 |year=2010 |month=October |pmid=20855837 |doi=10.1200/JCO.2010.29.6038 |url=}}</ref>
 
Note:
*Both ''gefitinib'' and ''erlotinib'' are also classified as ''tyrosine kinase inhibitors'' (TKI).


==Use==
==Use==

Revision as of 16:09, 29 March 2012

Epidermal growth factor receptor inhibitors, abbreviated EGFR inhibitors, is a class of drugs that blocks the EGF receptor.

Drugs

Note:

  • Both gefitinib and erlotinib are also classified as tyrosine kinase inhibitors (TKI).

Use

References

  1. 1.0 1.1 Sun Y, Ren Y, Fang Z, et al. (October 2010). "Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases". J. Clin. Oncol. 28 (30): 4616–20. doi:10.1200/JCO.2010.29.6038. PMID 20855837.